Aytu BioPharma, Inc. AYTU 深 滬
等待開盤 02-07 09:30:00 美东时间
2.39
+0.090
+3.91%
華盛通- 最 高2.50
- 今 開2.30
- 成交量 4.29万股
- 最 低 2.2826
- 昨 收 2.30
- 總市值 2565.24万
- 52周最高 3.065
- 市盈率 靜 --
- 換手率 0.40%
- 52周最低 0.95
- 委 比 -60.66%
- 總股本 1073.32万
- 歷史最高 12920.00
- 量 比 0.36
- 振 幅 9.45%
- 歷史最低 0.95
- 每 手 1
- 風險率 0.52%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Aytu BioPharma Q2 Earnings Report: What Investors Need to Know
The earnings results for Aytu BioPharma (NASDAQ:AYTU) for Q2 were made public o...
02-04 05:58
Aytu BioPharma Q2 revenue beats expectations
Aytu BioPharma Q2 revenue beats expectations Overview Pharmaceutical company's Q2 revenue beat analyst expectations Adjusted EBITDA for Q2 beat analyst expectations Outlook Company did not provide specific financial guidance for future quarters or full year in press release Result Drivers SHIFT IN M
02-04 05:21
Earnings Summary: Aytu BioPharma Q2
Aytu BioPharma (NASDAQ:AYTU) released its Q2 earnings on Tuesday, February 3, 2...
02-04 05:08
Aytu Biopharma meldet für das zweite Quartal (Q2) 2026 einen Nettoverlust von USD 10,58 Mio. und einen Rückgang des bereinigten EBITDA um 163 Prozent auf USD -0,80 Mio
Aytu Biopharma meldet für das zweite Quartal (Q2) 2026 einen Nettoverlust von USD 10,58 Mio. und einen Rückgang des bereinigten EBITDA um 163 Prozent auf USD -0,80 Mio Aytu Biopharma Inc. hat die Finanzergebnisse für das zweite Quartal des Geschäftsjahres 2026 veröffentlicht. Der Gesamtumsatz belief
02-04 05:06
Earnings Scheduled For February 3, 2026
Companies Reporting Before The Bell • Atkore (NYSE:ATKR) is expected to report ...
02-03 19:11
Aytu Biopharma Inc. to Report Second Quarter Results and Host Conference Call
Aytu Biopharma Inc. to Report Second Quarter Results and Host Conference Call Aytu BioPharma Inc. will report its fiscal 2026 second quarter operational and financial results after the market close on Tuesday, February 3, 2026. The company will host a conference call and webcast the same day at 4:30
01-28 05:05
Aytu BioPharma Announces Nationwide Commercial Launch Of EXXUA And Completion Of Launch Meeting Last Week That Finalized Sales Training And Launch Preparations For EXXUA
EXXUA addresses frequent causes of treatment discontinuation with first-line SSRIs and SNRIsNow commercially available through retail pharmacies and participating Aytu RxConnect® pharmacies to support patient
01-20 22:04
美股大行评级 | 超配！大摩上调回声星通信评级；汽车地带、CBRL、金宝汤、家得宝等遭多家大行下调目标价
今日重点评级关注：Ascendiant Capital：维持Lucid Diagnostics"买入"评级，目标价从8美元升至8.25美元；Ascendiant Capital：维持Aytu BioPharma"买入"评级，目标价从12.5美元升至13美元
2025-12-11 10:33
Ascendiant Capital Maintains Buy on Aytu BioPharma, Raises Price Target to $13
Ascendiant Capital analyst Edward Woo maintains Aytu BioPharma (NASDAQ:AYTU) with a Buy and raises the price target from $12.5 to $13.
2025-12-10 18:31
Aytu BioPharma Q1 Adj. EPS $(0.08) Beats $(0.23) Estimate, Sales $13.900M Beat $12.397M Estimate
Aytu BioPharma (NASDAQ:AYTU) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.23) by 65.22 percent. This is a 60 percent increase over losses of $(0.20) per share from the
2025-11-14 05:09
